Table 3. Basic information between OLNM and NOLNM groups in resectable ALK-rearranged NSCLC patients.
| Characteristics | NOLNM (n=426) | OLNM (n=88) | P |
|---|---|---|---|
| Age, years | 55.2±11.4 | 54.9±11.4 | 0.798 |
| Gender | 0.150 | ||
| Female | 258 (60.6) | 46 (52.3) | |
| Male | 168 (39.4) | 42 (47.7) | |
| Smoking history | 0.941 | ||
| Never | 352 (82.6) | 73 (83.0) | |
| Current or ever | 74 (17.4) | 15 (17.0) | |
| ECOG PS | 0.007 | ||
| ECOG PS 0 | 368 (86.4) | 66 (75.0) | |
| ECOG PS 1–2 | 58 (13.6) | 22 (25.0) | |
| pT stage | <0.001 | ||
| T1 | 352 (82.6) | 49 (55.6) | |
| T2 | 66 (15.5) | 27 (30.7) | |
| T3 | 7 (1.7) | 10 (11.4) | |
| T4 | 1 (0.2) | 2 (2.3) | |
| pN stage | <0.001 | ||
| N0 | 426 (100.0) | 0 (0.0) | |
| N1 | 0 (0.0) | 36 (40.9) | |
| N2 | 0 (0.0) | 52 (59.1) | |
| CT density | −137.5±214.0 | 9.0±80.8 | <0.001 |
| Tumor SUVmax | 6.3±4.3 | 9.4±5.9 | 0.011 |
| LN SUVmax | 1.1±1.8 | 1.3±2.6 | 0.676 |
| Location | 0.474 | ||
| Peripheral | 348 (81.7) | 68 (77.3) | |
| Central | 75 (17.6) | 20 (22.7) | |
| Unknown | 3 (0.7) | 0 (0.0) | |
| Clinical tumor size, mm | 17.7±9.3 | 24.5±13.4 | <0.001 |
| Pathology | 0.057 | ||
| Adenocarcinoma | 424 (99.6) | 86 (97.7) | |
| Adenosquamous carcinoma | 1 (0.2) | 0 (0.0) | |
| Sarcomatoid carcinoma | 0 (0.0) | 2 (2.3) | |
| Large cell carcinoma | 1 (0.2) | 0 (0.0) | |
| Histological differentiation | <0.001 | ||
| Well | 21 (4.9) | 1 (1.2) | |
| Moderate | 197 (46.2) | 15 (17.0) | |
| Poor | 206 (48.4) | 70 (79.5) | |
| Unknown | 2 (0.5) | 2 (2.3) | |
| Lateral | 0.394 | ||
| Left | 187 (43.9) | 43 (48.9) | |
| Right | 239 (56.1) | 45 (51.1) | |
| STAS | <0.001 | ||
| Yes | 203 (47.7) | 64 (72.7) | |
| No | 223 (52.3) | 24 (27.3) | |
| Vascular invasion | <0.001 | ||
| Yes | 21 (4.9) | 19 (21.6) | |
| No | 405 (95.1) | 69 (78.4) | |
| Operative procedure | 0.001 | ||
| Wedge resection | 9 (2.1) | 0 (0.0) | |
| Segmentectomy | 65 (15.3) | 3 (3.4) | |
| Lobectomy | 352 (82.6) | 85 (96.6) | |
| Mutation type | 0.511 | ||
| ALK | 415 (97.5) | 85 (96.5) | |
| ALK + EGFR 19-DEL | 6 (1.4) | 1 (1.2) | |
| ALK + EGFR L858R | 3 (0.7) | 2 (2.3) | |
| ALK + EGFR T790M | 1 (0.2) | 0 (0.0) | |
| ALK + KRAS | 1 (0.2) | 0 (0.0) | |
| Recurrence location | <0.001 | ||
| Local | 23 (5.4) | 14 (15.9) | |
| Distant | 7 (1.6) | 13 (14.8) | |
| None or missing | 396 (93.0) | 61 (69.3) |
Values are mean ± SD or n (%). NSCLC, non-small cell lung cancer; ECOG PS, Eastern Corporative Oncology Group Performance Status; pT stage, pathological T stage; pN stage, pathological N stage; CT, computed tomography; STAS, spread through air space; ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; KRAS, Kirsten rat sarcoma viral oncogene homolog; OLNM, occult lymph node metastasis; NOLNM, no occult lymph node metastasis; SUVmax, maximum standardized uptake value; LN, lymph node; SD, standard deviation.